Brexpiprazole · larger labeled portfolio than Fexofenadine
SPL labels Brexpiprazole + Fexofenadine as minor; Brexpiprazole 9 / Fexofenadine 1 in that band.
Mechanism on file: Brexpiprazole does not affect the transport protein responsible for moving fexofenadine through your body.
FDA SPL severity: Minor
Brexpiprazole + Fexofenadine · SPL mechanism field
Brexpiprazole does not affect the transport protein responsible for moving fexofenadine through your body.
Minor band excerpt · Brexpiprazole with Fexofenadine
Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI.
Brexpiprazole · 9 SPL pairs (broader portfolio than Fexofenadine)
- Bupropion minor
- Dextromethorphan minor
- Fluoxetine minor
- Lovastatin minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.